Project Grant R21CA297387

Award Date 7/11/25
Completion Date 6/30/27
Dollars Obligated $453K
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
This National Cancer Institute (CFDA 93.394 Cancer Detection and Diagnosis Research) Project Grant award of $683,089 to the Sloan-Kettering Institute for Cancer Research supports the development of an improved, interpretable deep learning algorithm called DeepLIIF for more reproducible and accurate PD-L1 immunohistochemistry (IHC) biomarker quantification. The goal is to leverage virtual multiplex immunofluorescence (MPIF) restaining and large, diverse datasets across lung and bladder cancers to...
The National Cancer Institute (NCI) awarded a $632,300 Project Grant under the Cancer Biology Research program (CFDA 93.396) to Carnegie Mellon University. The grant will fund the development of an integrated ultrahigh-throughput 3D volumetric super-resolution imaging system. This system will combine a multiscale fluorescence mesoscope with magnify expansion microscopy to enable rapid, large-area 3D imaging with exceptional subcellular detail. The goal is to study interactions between cancer and...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the Sloan-Kettering Institute for Cancer Research provides $1,313,806.00 in funding from August 13, 2024 through July 31, 2029. The grant supports the development and clinical translation of mesothelin-targeted chimeric antigen receptor (CAR) T-cell therapies for solid tumors. Key objectives include: Elucidating the mechanisms by which the KITV costimulatory domain enhances CAR T-cell...
The National Cancer Institute (NCI) awarded a $100,760 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Sloan-Kettering Institute for Cancer Research in New York, NY. The grant supports research to engineer biomaterials that can modulate the tumor immune microenvironment, with a focus on multiple myeloma. Specifically, the project aims to develop nanoparticle-based RNA interference therapy to inhibit key proteins (cyclophilin A and E-selectin) expressed by bone...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $730,398 to the Sloan-Kettering Institute for Cancer Research to investigate the relationship between leptomeningeal cancer cell growth and inflammatory signaling in the leptomeningeal space. The research aims to mechanistically dissect the CXCL1-CXCR2 signaling axis within the leptomeningeal space, identify cancer cell signals that provoke leptomeningeal CXCL1 generation, and...
This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $427,095 to Northeastern University to develop a novel microfluidic droplet-based platform (MDP) technology. The MDP will generate and analyze a 3D biomimetic multicellular immunogenic tumor model to: Establish multiple levels of hypoxia within the same tumor-chip for parallel processing. Investigate spatiotemporal interaction between the...
This $103,948 Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to the Sloan-Kettering Institute for Cancer Research supports research aimed at elucidating the mechanisms driving T-cell dysfunction within the tumor microenvironment. The research plan includes two main components: Predoctoral research (Aim 1) to investigate how local amino acid availability limits effector function in tumor-infiltrating T-cells, including profiling the...
This $435,827 Project Grant from the National Cancer Institute (NCI) under the CFDA 93.394 Cancer Detection and Diagnosis Research program supports research conducted by New York University (NYU) School of Medicine to develop deep learning methods for analyzing mass spectrometry imaging (MSI) data. The goal is to make MSI data more accessible to existing machine learning workflows by expanding the dimensionality of the data structure to treat each metabolite or lipid as an individual "color...
This $509,448 Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower program) supports research by The Leland Stanford Junior University to investigate antigen-presenting cells in lymph nodes and their role in modulating metastatic tumor progression. The key objectives are to: 1) identify the specific antigen-presenting cell populations responsible for promoting tumor-specific regulatory T cell development, and 2) assess therapeutic strategies to reprogram...
This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $650,450 to the University of Southern California to develop a novel cancer immunotherapy using genetically engineered CD4+ T cells targeting the CT83 tumor antigen. The research aims to determine the mechanisms by which these engineered T cells eliminate lung cancer cells, produce GMP-grade master cell banks and viral particles, and develop a scalable...

This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $452,540 to the Sloan-Kettering Institute for Cancer Research to develop a novel T-cell imaging paradigm that will enable real-time monitoring of endogenous T-cell trafficking, tumor targeting, and persistence in patients with multiple myeloma undergoing bispecific T-cell engager antibody (BiTEA) treatments. The goal is to better understand mechanisms of therapy resistance and improve efficacy, particularly for patients with extramedullary disease. The research aims to provide preclinical support and justification to advance this T-cell imaging approach into clinical application for multiple myeloma and other cancers undergoing immunotherapy with BiTEAs. The award period is from July 11, 2025 to June 30, 2027.

Generated 8/5/25, 3:46 AM